Dexferrum
(Iron dextran)ApprovedSmall molecule
Dexferrum is one of 47 small molecule programs targeting Anemia. It is currently in Approved.
1
Indications
10
Total Trials
0
Active Trials
46
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
74 competitors in Anemia
#DrugCompanyPhaseTrials
1Dacogen
Sun Pharmaceutical Industries, Inc.Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Orgovyx
Sumitomo Pharma America, Inc.Approved
Rayos
RRoxane Laboratories
Approved
Rituxan
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Dexferrum
NNew River Pharmaceuticals
Approved
Aldactone
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Iron deficiency anemia2 trials
Anemia2 trials
Iron-deficiency1 trial
Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Completed·—·N/A·NCT02889133·79 enrolled
Pregnancy1 trial
3 more indications
Hypophosphatemia1 trial
Children1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
INFED
NDA NDA017441
Jan 1, 1982
IRON DEXTRAN
NDA NDA010787
Jan 1, 1982
PROFERDEX
NDA NDA017807
Feb 23, 1996
DEXFERRUM
NDA NDA040024
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iron dextran. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- NNew River Pharmaceuticals